Vivos Therapeutics (VVOS) Research & Development (2020 - 2026)

Vivos Therapeutics (VVOS) has reported Research & Development for 7 consecutive years, with $155000.0 the latest figure, recorded in Q2 2026.

• On a quarterly basis, Research & Development fell 40.38% year-over-year to $155000.0 in Q2 2026; TTM through Jun 2026 was $1.2 million, a 13.59% decrease from a year earlier, with the FY2025 full-year figure at $1.4 million, down 19.12% from the prior year.
• Research & Development was $155000.0 for Q2 2026 at Vivos Therapeutics, down from $249000.0 in the prior quarter.
• Over five years, Research & Development peaked at $1.7 million in Q2 2022 and troughed at $155000.0 in Q2 2026.
• A 5-year average of $606666.7 and a median of $501000.0 in 2023 frame the typical range for Research & Development.
• Across the five-year window, Research & Development gained 21.53% in 2022 and sank 65.27% in 2023, its largest moves.
• Over 5 years, Research & Development stood at $1.4 million in 2022, then tumbled by 55.28% to $606000.0 in 2023, then plunged by 32.01% to $412000.0 in 2024, then fell by 7.28% to $382000.0 in 2025, then sank by 59.42% to $155000.0 in 2026.
• The last three Research & Development figures came in at $155000.0 (Q2 2026), $249000.0 (Q1 2026), and $382000.0 (Q4 2025), per Business Quant data.